Division of Drug Metabolism and Molecular Toxicology, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3, Aoba, Aramaki, Aoba-ku, Sendai, 980-8578, Japan.
J Pharmacol Exp Ther. 2011 Jan;336(1):188-96. doi: 10.1124/jpet.110.171736. Epub 2010 Sep 30.
In our study, ampicillin (AMP)-mediated decrease of enterobacteria caused increases in hepatic bile acid concentration through (at least in part) elevation of bile acid synthesis in C57BL/6N mice. We investigated the involvement of enterobacteria on intestinal bile acid absorption in AMP-treated mice in the present study. Fecal enterobacterial levels and fecal bile acid excretion rates were markedly decreased in mice treated with AMP (100 mg/kg) for 3 days, whereas bile acid concentrations in portal blood were significantly increased compared with those in mice treated with a vehicle. Ileal apical sodium-dependent bile acid transporter (SLC10A2) mRNA levels and ileal SLC10A2 protein levels in brush-border membranes were significantly increased compared with those in mice treated with the vehicle. In AMP-treated mice, total bile acid levels were increased, whereas levels of enterobacteria-biotransformed bile acid, taurodeoxycholic acid, and cholic acid were decreased in intestinal lumen. These phenomena were also observed in farnesoid X receptor-null mice treated with AMP for 3 days. Discontinuation of AMP administration after 3 days (vehicle administration for 4 days) increased levels of fecal enterobacteria, fecal bile acid excretion, and taurodeoxycholic acid and cholic acid in the intestinal lumen, whereas the discontinuation decreased ileal SLC10A2 expression and bile acid concentrations in the portal blood. Coadministration of taurodeoxycholic acid or cholic acid decreased ileal SLC10A2 expression in mice treated with AMP. These results suggest that enterobacteria-mediated bile acid biotransformation modulates intestinal bile acid transport and homeostasis through down-regulation of ileal SLC10A2 expression.
在我们的研究中,氨苄西林(AMP)介导的肠杆菌减少通过(至少部分)增加胆汁酸合成导致 C57BL/6N 小鼠肝胆汁酸浓度升高。本研究旨在研究 AMP 处理小鼠中肠内胆汁酸吸收中肠杆菌的参与。用 AMP(100mg/kg)处理 3 天的小鼠粪便肠杆菌水平和粪便胆汁酸排泄率明显降低,而门静脉血中胆汁酸浓度明显高于用载体处理的小鼠。与用载体处理的小鼠相比,回肠顶端钠依赖性胆汁酸转运体(SLC10A2)mRNA 水平和刷状缘膜 SLC10A2 蛋白水平显著增加。在 AMP 处理的小鼠中,总胆汁酸水平增加,而肠道腔中结合肠杆菌生物转化的胆汁酸、牛磺脱氧胆酸和胆酸水平降低。这些现象也在 AMP 处理 3 天的法尼醇 X 受体缺失小鼠中观察到。连续 3 天(连续 4 天给予载体)停用 AMP 后,粪便肠杆菌水平、粪便胆汁酸排泄和肠道腔中牛磺脱氧胆酸和胆酸水平增加,而停用 AMP 后回肠 SLC10A2 表达和门静脉血中胆汁酸浓度降低。牛磺脱氧胆酸或胆酸共给药可降低 AMP 处理小鼠的回肠 SLC10A2 表达。这些结果表明,肠杆菌介导的胆汁酸生物转化通过下调回肠 SLC10A2 表达来调节肠道胆汁酸转运和平衡。